MeSH term
Frequency | Condition_Probility | Humans | 258 | 0.0 |
English Abstract | 4 | 0.0 |
Animals | 131 | 0.0 |
Cell Line, Tumor | 6 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Gene Expression Profiling | 10 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 6 | 1.0 |
Immediate-Early Proteins/genetics | 2 | 4.0 |
Male | 20 | 0.0 |
Mice | 75 | 0.0 |
Mice, Nude | 4 | 0.0 |
Oligonucleotide Array Sequence Analysis | 12 | 1.0 |
Time Factors | 17 | 0.0 |
Base Sequence | 59 | 0.0 |
Binding Sites | 27 | 0.0 |
COS Cells | 9 | 0.0 |
Cell Line | 57 | 0.0 |
*Gene Expression Regulation | 17 | 0.0 |
Hela Cells | 15 | 0.0 |
Luciferases/metabolism | 6 | 0.0 |
Models, Genetic | 2 | 0.0 |
Molecular Sequence Data | 57 | 0.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Mutation | 13 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Phosphorylation | 28 | 0.0 |
RNA, Messenger/metabolism | 16 | 0.0 |
Rats | 34 | 0.0 |
Research Support, Non-U.S. Gov't | 189 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Transfection | 46 | 0.0 |
Tumor Cells, Cultured | 70 | 0.0 |
*Nuclear Proteins | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 98 | 0.0 |
Genetic Vectors | 6 | 0.0 |
Glutathione Transferase/metabolism | 4 | 0.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Protein Binding | 24 | 0.0 |
Protein Structure, Tertiary | 10 | 0.0 |
Proto-Oncogene Proteins c-jun/*metabolism | 12 | 15.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 16 | 0.0 |
Trans-Activation (Genetics) | 15 | 0.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
Aged | 6 | 0.0 |
Blotting, Northern | 11 | 0.0 |
Comparative Study | 28 | 0.0 |
Dose-Response Relationship, Drug | 11 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Female | 28 | 0.0 |
Gene Expression Regulation | 18 | 0.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Transcription Factor AP-1/*genetics/metabolism | 3 | 33.0 |
Transcription, Genetic | 29 | 0.0 |
Up-Regulation | 8 | 0.0 |
Cells, Cultured | 41 | 0.0 |
Enzyme Activation | 5 | 0.0 |
Gene Expression Regulation/drug effects/*physiology | 5 | 6.0 |
Genes, fos | 15 | 12.0 |
Genes, jun | 17 | 21.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 4 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 5 | 0.0 |
Transcription, Genetic/drug effects | 6 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 5 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 3 | 0.0 |
Cell Line, Transformed | 9 | 0.0 |
DNA/metabolism | 13 | 0.0 |
Trans-Activation (Genetics)/physiology | 2 | 2.0 |
*Ultraviolet Rays | 2 | 0.0 |
Cell Division | 15 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
G1 Phase | 2 | 0.0 |
Keratinocytes/metabolism | 3 | 2.0 |
Kinetics | 9 | 0.0 |
Ligands | 2 | 0.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
*Genes, jun | 18 | 41.0 |
Immunoenzyme Techniques | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Proto-Oncogene Proteins c-jun/metabolism | 14 | 10.0 |
Amino Acid Motifs | 2 | 0.0 |
Cell Nucleus/metabolism | 9 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
DNA-Binding Proteins/*metabolism | 12 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Genes, Reporter | 11 | 0.0 |
Immunoblotting | 2 | 0.0 |
NF-kappa B/*metabolism | 4 | 0.0 |
Promoter Regions (Genetics) | 27 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Signal Transduction | 18 | 0.0 |
Transcription Factor AP-1/*metabolism | 27 | 16.0 |
3T3 Cells | 11 | 0.0 |
Bone Morphogenetic Proteins/*pharmacology | 2 | 3.0 |
Enhancer Elements (Genetics) | 5 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Recombinant Fusion Proteins/metabolism | 8 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Signal Transduction/*drug effects | 3 | 0.0 |
Transcription Factor AP-1/genetics | 6 | 21.0 |
Transforming Growth Factor beta/*pharmacology | 11 | 2.0 |
ras Proteins/metabolism | 3 | 1.0 |
Blotting, Western | 14 | 0.0 |
Cell Transformation, Neoplastic/*metabolism | 2 | 5.0 |
Proto-Oncogene Proteins c-fos/*metabolism | 3 | 8.0 |
Transcription Factors/*metabolism | 9 | 0.0 |
Carcinogens/pharmacology | 3 | 3.0 |
MAP Kinase Kinase 1 | 2 | 1.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 2 | 1.0 |
Promoter Regions (Genetics)/physiology | 2 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 4 | 0.0 |
Proteins/genetics | 5 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 31 | 1.0 |
Transcription, Genetic/drug effects/physiology | 2 | 5.0 |
Gene Expression Regulation/*drug effects | 9 | 1.0 |
Growth Inhibitors/*pharmacology | 3 | 1.0 |
Interleukin-6/pharmacology | 3 | 1.0 |
Lymphokines/*pharmacology | 3 | 1.0 |
Promoter Regions (Genetics)/drug effects/genetics | 2 | 6.0 |
Transcription, Genetic/*drug effects | 13 | 3.0 |
Cercopithecus aethiops | 3 | 0.0 |
Colonic Neoplasms | 2 | 1.0 |
DNA Primers | 6 | 0.0 |
*Genes, Immediate-Early | 8 | 25.0 |
Genes, fos/drug effects | 7 | 30.0 |
Genes, jun/drug effects | 8 | 88.0 |
Glyceraldehyde-3-Phosphate Dehydrogenases/genetics | 2 | 5.0 |
Luciferases/genetics | 4 | 1.0 |
Protein-Tyrosine Kinase/metabolism | 6 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
Calcitriol/*pharmacology | 3 | 1.0 |
HL-60 Cells | 3 | 0.0 |
Oxidation-Reduction | 3 | 0.0 |
Proto-Oncogene Proteins c-fos/genetics/metabolism | 6 | 22.0 |
Proto-Oncogene Proteins c-jun/genetics/metabolism | 7 | 20.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Apoptosis | 5 | 0.0 |
Cell Differentiation | 8 | 0.0 |
Cycloheximide/pharmacology | 5 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Phenotype | 7 | 0.0 |
Transcription Factor AP-1/metabolism | 27 | 9.0 |
Gene Expression Regulation/*physiology | 4 | 1.0 |
*MAP Kinase Kinase Kinase 1 | 2 | 1.0 |
Protein Precursors/*genetics | 4 | 3.0 |
Transcription Factor AP-1/*physiology | 5 | 14.0 |
CD4-Positive T-Lymphocytes/*metabolism | 2 | 2.0 |
DNA-Binding Proteins/metabolism | 14 | 0.0 |
Lymphocyte Activation | 5 | 0.0 |
*Promoter Regions (Genetics) | 21 | 0.0 |
Proto-Oncogene Proteins c-fos/metabolism | 8 | 7.0 |
Trans-Activators/metabolism | 3 | 0.0 |
DNA | 3 | 0.0 |
Gene Expression Regulation/genetics | 4 | 2.0 |
Interleukin-1/physiology | 2 | 2.0 |
Proto-Oncogene Proteins c-jun/*genetics | 12 | 54.0 |
Gene Expression | 10 | 0.0 |
Middle Aged | 9 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Proto-Oncogene Proteins c-fos/biosynthesis/genetics | 3 | 25.0 |
Transcription Factor AP-1/*biosynthesis | 3 | 50.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Consensus Sequence | 5 | 0.0 |
Hydroquinones/*pharmacology | 2 | 11.0 |
Mutagenesis | 4 | 0.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 9 | 2.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 2 | 1.0 |
Plasmids/metabolism | 2 | 0.0 |
Transcription Factors/metabolism | 11 | 0.0 |
Protein Binding/physiology | 2 | 0.0 |
Signal Transduction/physiology | 4 | 0.0 |
Trans-Activators/*metabolism | 8 | 0.0 |
Transcription Factor AP-1/genetics/*metabolism | 5 | 19.0 |
Carcinogens/*pharmacology | 2 | 3.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
NF-kappa B/physiology | 2 | 2.0 |
Protein Kinase C/physiology | 3 | 1.0 |
Transcription Factor AP-1/physiology | 4 | 9.0 |
Transcription Factor AP-1/chemistry/*metabolism | 2 | 25.0 |
*Transcription, Genetic | 14 | 0.0 |
Fibroblasts/cytology | 2 | 0.0 |
Macromolecular Substances | 7 | 0.0 |
Oligodeoxyribonucleotides/metabolism | 2 | 4.0 |
Promoter Regions (Genetics)/*drug effects | 2 | 4.0 |
Regulatory Sequences, Nucleic Acid | 9 | 1.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Liver Neoplasms/metabolism | 2 | 2.0 |
DNA/genetics/metabolism | 3 | 0.0 |
DNA, Antisense/genetics | 2 | 4.0 |
Fibroblasts/physiology | 2 | 1.0 |
Genes, jun/genetics | 3 | 18.0 |
Keratinocytes/physiology | 2 | 9.0 |
Proto-Oncogene Proteins c-jun/*biosynthesis/genetics | 5 | 62.0 |
Trans-Activation (Genetics)/*physiology | 4 | 3.0 |
DNA-Binding Proteins/genetics/metabolism | 5 | 1.0 |
Mice, Knockout | 4 | 0.0 |
Signal Transduction/*physiology | 4 | 0.0 |
Transcription Factors/genetics/metabolism | 5 | 1.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
Jurkat Cells | 2 | 0.0 |
RNA, Messenger | 3 | 0.0 |
Repressor Proteins/*physiology | 2 | 1.0 |
T-Lymphocytes/metabolism | 3 | 1.0 |
Adult | 10 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cell Division/physiology | 2 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Keratinocytes/*cytology | 3 | 9.0 |
Organ Culture Techniques | 3 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Acetyltransferases/metabolism | 2 | 2.0 |
Chromatin/metabolism | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 8 | 0.0 |
Models, Biological | 7 | 0.0 |
Nuclear Proteins/*metabolism | 4 | 0.0 |
RNA/metabolism | 2 | 0.0 |
DNA Footprinting | 5 | 1.0 |
DNA-Binding Proteins/biosynthesis/genetics | 4 | 5.0 |
Protein Biosynthesis | 8 | 0.0 |
Transcription Factors/biosynthesis/genetics | 4 | 5.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Cell Division/drug effects | 13 | 0.0 |
*Cell Aging | 2 | 3.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Proto-Oncogene Proteins c-jun/biosynthesis/genetics | 4 | 36.0 |
RNA, Messenger/biosynthesis | 9 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Proto-Oncogene Proteins c-jun/*physiology | 6 | 27.0 |
Free Radical Scavengers/pharmacology | 2 | 3.0 |
JNK Mitogen-Activated Protein Kinases | 8 | 1.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Proto-Oncogene Proteins c-fos/*biosynthesis/genetics | 3 | 60.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Gene Expression/drug effects | 7 | 0.0 |
Immunohistochemistry | 9 | 0.0 |
Pregnancy | 5 | 0.0 |
Proto-Oncogene Proteins c-fos/genetics | 10 | 18.0 |
Proto-Oncogene Proteins c-jun/genetics | 14 | 35.0 |
RNA, Messenger/analysis | 10 | 0.0 |
Species Specificity | 2 | 0.0 |
Cyclins/genetics | 3 | 2.0 |
Thymidine/metabolism | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
*Cell Differentiation | 3 | 1.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Serum Response Factor | 2 | 1.0 |
In Vitro | 11 | 0.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Lymphocyte Activation/genetics | 3 | 3.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Apoptosis/*drug effects | 4 | 0.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Cell Transformation, Viral | 2 | 0.0 |
DNA/*metabolism | 3 | 0.0 |
Genes, fos/genetics/physiology | 2 | 100.0 |
Genes, jun/genetics/physiology | 2 | 100.0 |
Human T-lymphotropic virus 1/*metabolism | 2 | 10.0 |
*Trans-Activation (Genetics) | 10 | 1.0 |
Adolescent | 3 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Sequence Deletion | 8 | 0.0 |
*Signal Transduction | 5 | 0.0 |
Skin/*metabolism | 2 | 1.0 |
Tamoxifen/pharmacology | 3 | 3.0 |
Transcription Factor AP-1/*genetics | 6 | 30.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Protein p16/biosynthesis | 2 | 10.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Nuclear Proteins/metabolism | 8 | 0.0 |
Sequence Homology, Nucleic Acid | 9 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Proto-Oncogene Proteins c-jun/*biosynthesis | 6 | 66.0 |
Dimerization | 2 | 0.0 |
Fibroblast Growth Factor 2/*pharmacology | 2 | 1.0 |
Gene Deletion | 2 | 0.0 |
Phorbol Esters/pharmacology | 2 | 1.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 6 | 0.0 |
Proto-Oncogene Proteins c-jun/chemistry/genetics/*metabolism | 2 | 40.0 |
RNA, Messenger/genetics/metabolism | 8 | 0.0 |
Receptors, Estrogen/genetics/metabolism | 2 | 6.0 |
Transcription, Genetic/genetics | 3 | 0.0 |
Binding, Competitive | 2 | 0.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
HIV-1/*genetics | 2 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Signal Transduction/genetics | 4 | 1.0 |
Cell Survival/drug effects | 3 | 0.0 |
Genes, Immediate-Early | 3 | 5.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Genes, jun/*drug effects | 5 | 55.0 |
Promoter Regions (Genetics)/drug effects | 2 | 1.0 |
Protein Kinase C/antagonists & inhibitors/metabolism | 2 | 2.0 |
Trans-Activation (Genetics)/drug effects | 3 | 1.0 |
Cyclosporine/*pharmacology | 2 | 1.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Proto-Oncogene Proteins c-jun/*genetics/metabolism | 4 | 44.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Molecular Weight | 2 | 0.0 |
Proto-Oncogene Proteins c-fos/*analysis | 2 | 28.0 |
Proto-Oncogene Proteins c-jun/*analysis | 2 | 66.0 |
Aged, 80 and over | 2 | 0.0 |
Reference Values | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Fibroblasts/drug effects/metabolism | 2 | 1.0 |
Hybrid Cells | 2 | 0.0 |
Papillomavirus, Human/*genetics | 3 | 4.0 |
Proto-Oncogene Proteins c-fos/genetics/*metabolism | 2 | 8.0 |
DNA-Binding Protein, Cyclic AMP-Responsive | 2 | 8.0 |
*DNA-Binding Proteins | 7 | 0.0 |
Gene Expression Regulation/drug effects | 6 | 0.0 |
Proto-Oncogene Proteins c-fos/*genetics | 4 | 16.0 |
Proto-Oncogene Proteins c-jun/biosynthesis/*physiology | 3 | 75.0 |
Antigens, CD/metabolism | 2 | 0.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
Genes, fos/genetics | 3 | 6.0 |
Up-Regulation/genetics/immunology | 2 | 3.0 |
DNA, Complementary/genetics | 2 | 0.0 |
*Genes, p53 | 2 | 0.0 |
Dactinomycin/pharmacology | 4 | 1.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Cell Adhesion | 3 | 0.0 |
Epidermal Growth Factor/*pharmacology | 3 | 0.0 |
*Gene Expression | 5 | 0.0 |
Genes, jun/*genetics | 5 | 71.0 |
Genes, myc/*genetics | 2 | 2.0 |
Binding Sites/genetics | 3 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 4 | 1.0 |
Cytokines/genetics | 4 | 3.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Genes, Immediate-Early/*genetics | 2 | 22.0 |
Proto-Oncogenes/*genetics | 2 | 2.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Down-Regulation | 6 | 0.0 |
Enhancer Elements (Genetics)/physiology | 2 | 20.0 |
Amino Acid Sequence | 8 | 0.0 |
Interleukin-2/pharmacology | 3 | 0.0 |
DNA-Binding Proteins/*genetics | 7 | 0.0 |
Drug Synergism | 3 | 0.0 |
*Genes, fos | 6 | 9.0 |
Thionucleotides/pharmacology | 2 | 3.0 |
Transcription Factors/*genetics | 6 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Exons/genetics | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Zinc Fingers/genetics | 3 | 1.0 |
Neoplasm Proteins/biosynthesis | 3 | 3.0 |
*Oncogenes | 2 | 0.0 |
Proto-Oncogene Proteins c-fos/biosynthesis | 4 | 12.0 |
Proto-Oncogene Proteins c-jun/biosynthesis | 5 | 25.0 |
Genes, Immediate-Early/*drug effects | 3 | 75.0 |
In Situ Hybridization | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
DNA, Neoplasm/metabolism | 2 | 1.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Genes, ras | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/genetics | 3 | 5.0 |
Transformation, Genetic | 2 | 1.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
*Genes, src | 2 | 5.0 |
Proto-Oncogenes | 2 | 1.0 |
Gene Expression Regulation/drug effects/genetics | 2 | 14.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/physiology | 2 | 5.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/*metabolism | 3 | 4.0 |
Phosphoprotein Phosphatase/antagonists & inhibitors/*physiology | 2 | 22.0 |
Proto-Oncogenes/genetics | 3 | 9.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 3 | 1.0 |
Cyclic AMP/physiology | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 6 | 2.0 |
*Repressor Proteins | 5 | 0.0 |
Epidermal Growth Factor/pharmacology | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Transcription Factors/genetics | 4 | 0.0 |
Interleukin-6/*pharmacology | 6 | 2.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Carbachol/pharmacology | 2 | 2.0 |
Genes, fos/*genetics | 2 | 10.0 |
Infant, Newborn | 3 | 0.0 |
Receptors, Chemokine/biosynthesis/genetics | 2 | 11.0 |
Neuroblastoma | 2 | 1.0 |
RNA, Messenger/genetics | 12 | 0.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Cytokines/*physiology | 2 | 1.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Insulin/pharmacology | 2 | 0.0 |
*Mitogen-Activated Protein Kinases | 3 | 0.0 |
Retinoblastoma Protein/metabolism | 3 | 0.0 |
Multigene Family | 3 | 0.0 |
Proto-Oncogene Proteins c-fos/*biosynthesis | 3 | 21.0 |
Keratinocytes/*metabolism | 3 | 3.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Genes, myc | 3 | 1.0 |
Point Mutation | 2 | 0.0 |
Recombinant Proteins | 3 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Rabbits | 3 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Sheep | 2 | 0.0 |
Nerve Tissue Proteins/*genetics | 2 | 0.0 |
Vasoactive Intestinal Peptide/*genetics | 2 | 10.0 |
Proto-Oncogene Proteins c-jun/genetics/*metabolism | 5 | 15.0 |
Transcription Factors/genetics/*metabolism | 4 | 0.0 |
Collagen/genetics | 2 | 2.0 |
Collagenases/genetics | 3 | 15.0 |
Trans-Activation (Genetics)/*drug effects | 2 | 2.0 |
*Trans-Activators | 5 | 0.0 |
Protein Kinase Inhibitors | 2 | 1.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Protein Kinases/*metabolism | 3 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Growth Inhibitors/*physiology | 2 | 5.0 |
DNA Primers/chemistry | 3 | 0.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
Trans-Activators/*genetics | 3 | 0.0 |
*Transcription Factors | 5 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
*Immediate-Early Proteins | 4 | 1.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Proto-Oncogene Proteins c-jun/physiology | 2 | 14.0 |
Anticarcinogenic Agents/*pharmacology | 2 | 2.0 |
Proto-Oncogenes/drug effects | 5 | 55.0 |
*Gene Expression Regulation, Viral | 3 | 1.0 |
NF-kappa B/*physiology | 2 | 2.0 |
Transcription Factor, Sp1/metabolism | 2 | 0.0 |
Transcription Factor AP-1/genetics/*physiology | 3 | 42.0 |
Proto-Oncogene Proteins c-raf | 2 | 1.0 |
Proto-Oncogene Proteins c-jun/*genetics/*metabolism | 2 | 100.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
*Proto-Oncogenes | 3 | 0.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Neoplasm Proteins/*biosynthesis/genetics | 3 | 1.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine | 2 | 3.0 |
Isoquinolines/pharmacology | 2 | 1.0 |
Oncogene Proteins, Viral/*physiology | 3 | 8.0 |
Piperazines/pharmacology | 2 | 1.0 |
DNA/genetics | 2 | 0.0 |
Cell Division/genetics | 3 | 0.0 |
*Genes, myc | 3 | 1.0 |
Glioma | 2 | 2.0 |
Genes, myc/drug effects | 2 | 13.0 |
Organ Specificity | 2 | 0.0 |
Proto-Oncogene Proteins c-jun/biosynthesis/*genetics | 2 | 66.0 |
Genistein | 2 | 2.0 |
Isoflavones/pharmacology | 2 | 3.0 |
Quinones/pharmacology | 2 | 1.0 |
DNA Mutational Analysis | 3 | 0.0 |
Protein Precursors/*biosynthesis/genetics | 2 | 20.0 |
DNA-Binding Proteins/*biosynthesis | 2 | 1.0 |
Gene Expression/*drug effects | 3 | 1.0 |
Oligonucleotide Probes | 3 | 0.0 |
Transcription Factors/*biosynthesis | 2 | 1.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Caco-2 Cells | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Gene Expression Regulation/physiology | 3 | 1.0 |
Transforming Growth Factor beta/*physiology | 3 | 2.0 |
Chickens | 2 | 0.0 |
Leucine Zippers | 2 | 1.0 |
Cell Cycle/*drug effects | 2 | 1.0 |
Cyclins/metabolism | 2 | 0.0 |
Lung/cytology | 2 | 3.0 |
Mink | 2 | 3.0 |
Mitosis/drug effects | 2 | 1.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Ethers, Cyclic/*pharmacology | 3 | 25.0 |
Okadaic Acid | 3 | 6.0 |
Phosphoprotein Phosphatase/*antagonists & inhibitors | 2 | 12.0 |
Proto-Oncogene Proteins c-fos/biosynthesis/physiology | 2 | 100.0 |
Cell Differentiation/drug effects/genetics | 2 | 3.0 |
Calcimycin/pharmacology | 2 | 0.0 |
Cell Nucleus/physiology | 2 | 2.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
Oligodeoxyribonucleotides/chemistry | 4 | 1.0 |
Receptors, Immunologic/*physiology | 2 | 1.0 |
*Genes, ras | 2 | 0.0 |
T-Lymphocytes/*drug effects | 2 | 2.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 2 | 2.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Forskolin/pharmacology | 3 | 0.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
Transcription Factors | 2 | 2.0 |
*Lymphocyte Activation | 2 | 0.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
Transcription Factors/*genetics/metabolism | 3 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
*Cell Division | 2 | 1.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Proto-Oncogene Proteins c-fos | 3 | 5.0 |
Proto-Oncogene Proteins c-jun | 8 | 16.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Protein Kinases/metabolism | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Drug Interactions | 2 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Cell Cycle Proteins/metabolism | 2 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
*Gene Amplification | 2 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Immediate-Early Proteins/*biosynthesis | 2 | 28.0 |
